New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:25 EDTBA, BA, LLY, LLYSenate Judiciary Committee to hold a hearing
The Subcommittee on Crime and Terrorism holds a hearing entitled, "Economic Espionage and Trade Secret Theft: Are Our Laws Adequate for Today’s Threats? with Vice President Paul Hoffman of The Boeing Company and Vice President Doug Norman of Eli Lilly & Company on May 13 at 2:30 pm. Webcast Link
News For BA;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
15:17 EDTBANegotiators compromise on highway bill, to revive Ex-Im bank, Bloomberg reports
Subscribe for More Information
13:02 EDTLLYEli Lilly says trial data shows Trulicity effective as add-on treatment
New data from a completed Phase 3 trial show Trulicity 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1C from baseline after 24 weeks of treatment, Eli Lilly said. Trulicity is Eli Lilly's once-weekly glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. These data, from the Trulicity AWARD-8 clinical trial, were presented for the first time today at the 2015 International Diabetes Federation World Diabetes Congress in Vancouver, Canada. "For patients who cannot tolerate or have contraindications to metformin, a sulfonylurea is often prescribed as first-line therapy for type 2 diabetes," said Kathleen Dungan, M.D., endocrinologist, associate professor, The Ohio State University Wexner Medical Center, and lead study author. "This study affirms that Trulicity is efficacious and well-tolerated as an add-on to sulfonylurea therapy, which can help prescribers make treatment decisions for their individual patients."
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Outperform from Neutral at Credit Suisse... Allstate (ALL) upgraded to Neutral from Sell at Citi... Campbell Soup (CPB) upgraded to Buy from Hold at Argus... Cenovus Energy (CVE) upgraded to Neutral from Sell at Goldman... Computer Programs (CPSI) upgraded to Hold from Sell at Deutsche Bank... Concho Resources (CXO) upgraded to Strong Buy from Outperform at Raymond James... Conn's (CONN) upgraded to Buy from Hold at Stifel... Delta Lloyd (DLLLY) upgraded to Neutral from Underweight at JPMorgan... Eli Lilly (LLY) assumed with an Overweight from Equal Weight at Barclays... HF Financial (HFFC) upgraded to Buy from Hold at Sandler O'Neill... Johnson & Johnson (JNJ) upgraded to Overweight from Equal Weight at Barclays... KPN (KKPNY) upgraded to Buy from Neutral at Nomura... Merck (MRK) assumed with an Overweight from Equal Weight at Barclays... Monsanto (MON) upgraded to Overweight from Neutral at Atlantic Equities... Nokia (NOK) upgraded to Outperform from Neutral at Credit Suisse... Parkway Properties (PKY) upgraded to Buy from Hold at Stifel... Pioneer Natural (PXD) upgraded to Strong Buy from Outperform at Raymond James... Rackspace (RAX) upgraded to Outperform from Sector Perform at RBC Capital... TerraForm Power (TERP) upgraded to Outperform from Perform at Oppenheimer... Windstream (WIN) upgraded to Outperform from Market Perform at Raymond James... Yum! Brands (YUM) upgraded to Outperform from Market Perform at Cowen.
09:34 EDTLLYBarclays biopharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
07:24 EDTBABoeing likely to boost dividend, buyback this month, says Deutsche Bank
Deutsche Bank analyst Myles Walton expects Boeing's board to announce the outcome of their annual capital deployment meeting on December 14. He believes the company will boost its dividend by 15% and increase its outstanding share repurchase authorization to $12B from the around $5B remaining. Walton views the capital deployment decision as a year-end catalyst for Boeing shares. He keeps a Buy rating on the name with a $175 price target.
05:43 EDTLLYEli Lilly assumed with an Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Eli Lilly (LLY) to Overweight after assuming coverage of the name. Good execution for Cyramza and Jardiance should drive continued share outperformance, Meacham tells investors in a research note. He raised his price target for shares to $95 from $75. Lilly closed yesterday down $1.43 to $82.22. The analyst this morning also upgraded Johnson & Johnson (JNJ) and Merck (MRK) to Overweight and downgraded AbbVie (ABBV) to Equal Weight.
November 30, 2015
18:25 EDTBABoeing awarded $134M government contract
Subscribe for More Information
November 29, 2015
20:16 EDTBAFAA to propose new safety directives for some Boeing, Embraer jets, WSJ says
Subscribe for More Information
November 24, 2015
14:43 EDTLLYEli Lilly confirms FDA approval of Portrazza
Subscribe for More Information
11:48 EDTLLYFDA approves Portrazza to treat NSCLC
Subscribe for More Information
05:32 EDTBABoeing and BOC Aviation announce order for 22 737s
Subscribe for More Information
05:27 EDTBABoeing, EVA Airways finalize commercial airplane purchase
Subscribe for More Information
November 23, 2015
17:47 EDTBABoeing awarded $261.98M government contract
Boeing has been awarded a $261.98M firm-fixed-price, undefinitized contract action for delivery order to previously awarded contract FA8213-15-D-0002 for lot 19 Joint Direct Attack Munition, or JDAM, tailkits. Contractor will provide JDAM strap-on inertial guidance kits with the capability to receive guidance updates from Global Positioning Systems to increase weapon accuracy for conventional inventory bombs. Work will be performed at St. Louis, Missouri, and is expected to be complete by Nov. 20, 2017. Fiscal 2014, 2015 and 2016 ammunition funds in the amount of $13.28M are being obligated at the time of award. Air Force Life Cycle Management Center, Hill Air Force Base, Utah, is the contracting activity.
16:21 EDTBAAerojet Rocketdyne signs contract to support new era of spaceflight in U.S.
Aerojet Rocketdyne, a subsidiary of Aerojet Rocketdyne Holdings (AJRD), has signed a contract with Boeing (BA) valued at nearly $200M that supports a new era of spaceflight - one that will carry humans to the International Space Station from American soil once again. Under its Commercial Crew Transportation Capability subcontract to Boeing, Aerojet Rocketdyne is completing the design, development, qualification, certification and initial production of the Crew Space Transportation, or CST,-100 "Starliner" service module propulsion system. A CST-100 Starliner partner and team member since 2010, Aerojet Rocketdyne's work continues the development of the service module and launch abort propulsion system from prior commercial crew contracts with Boeing.
November 22, 2015
18:29 EDTBADelta CEO says Boeing offered used 777s for $10M, Bloomberg reports
Subscribe for More Information
November 19, 2015
06:34 EDTLLYEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:11 EDTLLYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:09 EDTLLYValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information
November 17, 2015
07:44 EDTBAInterest rate increases usually a bullish signal for Boeing, says Canaccord
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use